Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.01 USD
Change Today +0.01 / 0.20%
Volume 1.7M
OREX On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

orexigen therapeutics inc (OREX) Snapshot

Open
$4.99
Previous Close
$5.00
Day High
$5.09
Day Low
$4.92
52 Week High
03/3/15 - $9.37
52 Week Low
10/13/14 - $3.11
Market Cap
627.4M
Average Volume 10 Days
5.3M
EPS TTM
$-0.26
Shares Outstanding
125.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OREXIGEN THERAPEUTICS INC (OREX)

orexigen therapeutics inc (OREX) Related Businessweek News

View More BusinessWeek News

orexigen therapeutics inc (OREX) Details

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products in the United States. The company offers Contrave for the treatment of obesity. It has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave in Canada and Mexico. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.

47 Employees
Last Reported Date: 02/27/15
Founded in 2002

orexigen therapeutics inc (OREX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $640.6K
Chief Business & Financial Officer and Treasu...
Total Annual Compensation: $379.3K
Head of Global Development and Executive Vice...
Total Annual Compensation: $379.3K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $379.3K
Compensation as of Fiscal Year 2014.

orexigen therapeutics inc (OREX) Key Developments

Orexigen Therapeutics Announces Early Termination of Contrave Trial

Orexigen Therapeutics announced the early termination of the Light Study, a cardiovascular (CV) outcomes trial that compared its obesity drug Contrave to placebo, in addition to diet and exercise counseling, in 8,909 overweight and obese patients with certain CV risk factors. The study was terminated as an executive steering committee decided the company compromised the trial by prematurely releasing interim data two months ago. Orexigen countered that since continuation of the Light Study was not a post marketing requirement (PMR), and the majority of patients are no longer on blinded study drug, it had long advocated shutting down the study in December 2014, corresponding with the time of the 50% interim analysis, and focusing resources on new studies to further evaluate the therapeutic profile of Contrave. There have been a lot of challenges surrounding the use of interim data from ongoing studies for regulatory purposes. There are competing tensions for data confidentiality to preserve study integrity, transparency laws, and guidelines from regulatory bodies. With respect to the Light Study, Orexigen filed patent applications based on the unexpected result of the 25% interim analysis of LIGHT Study data.

Orexigen Therapeutics, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 01:00 PM

Orexigen Therapeutics, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 01:00 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Michael A. Narachi, Chief Executive Officer, President and Director.

Orexigen Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Orexigen Therapeutics, Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, total revenues were $4,359,000 against $857,000 a year ago. Loss from operations was $15,467,000 against $23,154,000 a year ago. Interest income was $63,000 against $26,000 a year ago. Net loss was $17,233,000 against $24,898,000 a year ago. Net income per share - basic and diluted was $0.14 against $0.23 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OREX:US $5.01 USD +0.01

OREX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $4.19 USD -0.01
GlaxoSmithKline PLC 1,465 GBp +14.00
Novo Nordisk A/S kr388.00 DKK +3.50
VIVUS Inc $2.53 USD -0.05
View Industry Companies
 

Industry Analysis

OREX

Industry Average

Valuation OREX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.5x
Price/Book 51.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OREXIGEN THERAPEUTICS INC, please visit www.orexigen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.